Patent application number | Description | Published |
20120164243 | Compositions and Methods for Improving Mitochondrial Function and Treating Neurodegenerative Diseases and Cognitive Disorders - Provided are compositions comprising compounds or precursors to compounds which may be used for a variety of therapeutic applications including, for example, treating and/or preventing a disease or disorder related to reduced or inadequate mitochondrial activity, including aging or stress, diabetes, obesity, and neurodegenerative diseases. The compounds relate generally to urolithins and precursors thereof, including but not limited to ellagitannins and urolithin A. In certain embodiments the compositions are presented in or as food products or nutritional supplements. These same compounds and compositions can also be used advantageously in generally healthy individuals to increase or maintain metabolic rate, decrease percent body fat, increase or maintain muscle mass, manage body weight, improve or maintain mental performance (including memory), improve or maintain muscle performance, improve or maintain mood, and manage stress. | 06-28-2012 |
20140018415 | Enhancing Autophagy or Increasing Longevity by Administration of Urolithins or Precursors Thereof - Disclosed are methods, compounds, and compositions useful for increasing autophagy and promoting longevity. The methods, compounds, and compositions relate to urolithins and urolithin precursors and use thereof. Certain urolithins are represented by Formula I, while certain urolithin precursors are represented by Formula IV. The urolithin may be urolithin A, urolithin B, urolithin C, or urolithin D. The urolithin precursor may be ellagic acid or an ellagitannin. The methods include in vivo, ex vivo, and in vitro uses of the compounds and compositions. | 01-16-2014 |
20160000753 | Enhancing Autophagy or Increasing Longevity by Administration of Urolithins or Precursors Thereof - Disclosed are methods, compounds, and compositions useful for increasing autophagy and promoting longevity. The methods, compounds, and compositions relate to urolithins and urolithin precursors and use thereof. Certain urolithins are represented by Formula I, while certain urolithin precursors are represented by Formula IV. The urolithin may be urolithin A, urolithin B, urolithin C, or urolithin D. The urolithin precursor may be ellagic acid or an ellagitannin. The methods include in vivo, ex vivo, and in vitro uses of the compounds and compositions. | 01-07-2016 |
Patent application number | Description | Published |
20080287520 | Use of Melatonin in Preventing Postoperative Complications - The invention relates to the use of melatonin, either alone or in combination with at least one compound selected from the group consisting of L-arginine, a physiologically acceptable salt thereof, one or more other physiologically acceptable compounds associated with the synthesis of nitric oxide and mixtures thereof, for the manufacture of a medicament for the therapeutic treatment, prophylactic treatment and/or prevention of postoperative infectious and/or non-infections complications induced by surgical interventions wherein the infectious complications may be pneumonia, wound infection (wound dehiscence), intra-abdominal abscess, and urinary tract infections (UTI) or wherein the non-infectious complication may be anastomotic leak, a pharmaceutical formulation comprising melatonin and at least one compound selected from the group consisting of L-arginine, a physiologically acceptable salt thereof, one or more other physiologically acceptable compounds associated with the synthesis of nitric oxide and mixtures thereof and a method for the therapeutic and/or prophylactic treatment of postoperative infectious and/or non-infectious complications induced by surgical interventions. | 11-20-2008 |
20120178787 | MELATONIN AND ITS USE IN PREVENTING POSTOPERATIVE COMPLICATIONS - The invention relates to the use of melatonin, either alone or in combination with at least one compound selected from the group consisting of L-arginine, a physiologically acceptable salt thereof, one or more other physiologically acceptable compounds associated with the synthesis of nitric oxide and mixtures thereof, for the manufacture of a medicament for the therapeutic treatment, prophylactic treatment and/or prevention of postoperative infectious and/or non-infections complications induced by surgical interventions wherein the infectious complications may be pneumonia, wound infection (wound dehiscence), intra-abdominal abscess, and urinary tract infections (UTI) or wherein the non-infectious complication may be anastomotic leak, a pharmaceutical formulation comprising melatonin and at least one compound selected from the group consisting of L-arginine, a physiologically acceptable salt thereof, one or more other physiologically acceptable compounds associated with the synthesis of nitric oxide and mixtures thereof and a method for the therapeutic and/or prophylactic treatment of postoperative infectious and/or non-infectious complications induced by surgical interventions. | 07-12-2012 |
20140249198 | MELATONIN AND ITS USE IN PREVENTING POSTOPERATIVE COMPLICATIONS - The invention relates to the use of melatonin, either alone or in combination with at least one compound selected from the group consisting of L-arginine, a physiologically acceptable salt thereof, one or more other physiologically acceptable compounds associated with the synthesis of nitric oxide and mixtures thereof, for the manufacture of a medicament for the therapeutic treatment, prophylactic treatment and/or prevention of postoperative infectious and/or non-infections complications induced by surgical interventions wherein the infectious complications may be pneumonia, wound infection (wound dehiscence), intra-abdominal abscess, and urinary tract infections (UTI) or wherein the non-infectious complication may be anastomotic leak, a pharmaceutical formulation comprising melatonin and at least one compound selected from the group consisting of L-arginine, a physiologically acceptable salt thereof, one or more other physiologically acceptable compounds associated with the synthesis of nitric oxide and mixtures thereof and a method for the therapeutic and/or prophylactic treatment of postoperative infectious and/or non-infectious complications induced by surgical interventions. | 09-04-2014 |
Patent application number | Description | Published |
20150107610 | FLAVOURED RODS FOR USE IN AEROSOL-GENERATING ARTICLES - A rod is provided, formed from a first sheet including a tobacco material and a second sheet including a non-tobacco flavourant, the first and second sheets being gathered together and circumscribed by a wrapper. The rod may be used as a component part of an aerosol-generating article. | 04-23-2015 |
20150107611 | ELECTRICALLY OPERATED AEROSOL GENERATING SYSTEM - A rod is provided, formed from a first sheet including an aerosol-forming material and a second sheet including a non-tobacco material, the first and second sheets being gathered together and circumscribed by a wrapper. The rod may be used as a component part of an aerosol-generating article. The second sheet preferably includes a material configured to modify an aerosol evolved from the aerosol-forming material or to modify other properties of the rod. | 04-23-2015 |
20150150302 | BLENDED RODS FOR USE IN AEROSOL-GENERATING ARTICLES - A rod for an aerosol-generating article is provided, including at least two sheets of tobacco material gathered together and circumscribed by a wrapper. The rod includes a first sheet of a first tobacco material and a second sheet of a second tobacco material. The second sheet of the second tobacco material is physically or chemically different to the first sheet of the first tobacco material. | 06-04-2015 |
20150163859 | HEATING ASSEMBLY FOR AN AEROSOL GENERATING SYSTEM - A heating assembly for heating an aerosol-forming substrate is provided, including: a heater including an electrically resistive heating element and a heater substrate; and a heater mount coupled to the heater; wherein the heating element includes a first portion and a second portion configured such that, when an electrical current is passed through the heating element, the first portion is heated to a higher temperature than the second portion as a result of the electrical current; and wherein the heater mount surrounds the second portion of the heating element. | 06-11-2015 |
Patent application number | Description | Published |
20090076477 | Automatic Liquid Injection System and Method - A power assisted method and injector device for controllably delivering to patients a dispersion medicament or diagnostically active agent, the homogeneity of which is preserved throughout delivery. Diagnostically active agents disclosed are gas microbubble suspensions useful in ultrasonic diagnostic imaging and liposomal formulations in which liposome vesicles are loaded with iodinated compounds. | 03-19-2009 |
20110150778 | Assembly of Gas-Filled Microvesicle With Active Component For Contrast Imaging - Assembly comprising a gas-filled microvesicle and a structural entity which is capable to associate through an electrostatic interaction to the outer surface of said microvesicle (microvesicle associated component—MAC), thereby modifying the physico-chemical properties thereof. Said MAC comprises a targeting ligand a diagnostic agent or any combination thereof. Optionally a bioactive agent can further be associated to the MAC. The assembly of the invention can be formed from gas-filled microbubbles or microballoons and a MAC having preferably nanometric dimensions, e.g. a micelle, and is used as an active component in diagnostically and/or therapeutically active formulations, in particular for enhancing the imaging in the field of ultrasound contrast imaging, including targeted ultrasound imaging, ultrasound-mediated drug delivery and other imaging techniques such as molecular resonance imaging (MRI) or nuclear imaging. | 06-23-2011 |
20110236320 | Ultrasound Contrast Agents And Process For The Preparation Thereof - Injectable aqueous suspension of microbubbles filled with a biocompatible gas and a method of preparation thereof. At least 10% of the total volume of gas contained in the microbubbles is contained in microbubbles with a diameter of 1.5 μm or less. The microbubbles can be obtained by preparing an emulsion comprising an aqueous medium, a phospholipid and a water immiscible organic solvent. The emulsion is then freeze-dried and then reconstituted in an aqueous suspension of gas-filled microbubbles. | 09-29-2011 |
20110245663 | Automatic Liquid Injection System and Method - A power assisted method and injector device for controllably delivering to patients a dispersion medicament or diagnostically active agent, the homogeneity of which is preserved throughout delivery. Diagnostically active agents disclosed are gas microbubble suspensions useful in ultrasonic diagnostic imaging and liposomal formulations in which liposome vesicles are loaded with iodinated compounds. | 10-06-2011 |
20110262366 | COMPOUNDS FOR TARGETING ENDOTHELIAL CELLS, COMPOSITIONS CONTAINING THE SAME AND METHODS FOR THEIR USE - The present invention provides compounds for targeting endothelial cells, tumor cells or other cells that express the NP-1 receptor, compositions containing the same and methods for their use. Additionally, the present invention includes diagnostic, therapeutic and radiotherapeutic compositions useful for visualization, therapy or radiotherapy. | 10-27-2011 |
20120093732 | ULTRASOUND CONTRAST AGENTS AND METHODS OF MAKING AND USING THEM - The invention is directed to injectable suspensions of gas-filled microvesicles, as well as methods of preparing and using the same, especially as ultrasound contrast agents. | 04-19-2012 |
20120265065 | Automatic Liquid Injection System and Method - A power assisted method and injector device for controllably delivering to patients a dispersion medicament or diagnostically active agent, the homogeneity of which is preserved throughout delivery. Diagnostically active agents disclosed are gas microbubble suspensions useful in ultrasonic diagnostic imaging and liposomal formulations in which liposome vesicles are loaded with iodinated compounds. | 10-18-2012 |
20130101520 | ULTRASOUND CONTRAST AGENTS AND METHODS OF MAKING AND USING THEM - The invention is directed to injectable suspensions of gas-filled microvesicles, as well as methods of preparing and using the same, especially as ultrasound contrast agents. | 04-25-2013 |
20130101522 | Ultrasound Contrast Agents And Process For The Preparation Thereof - Injectable aqueous suspension of microbubbles filled with a biocompatible gas and a method of preparation thereof. At least 10% of the total volume of gas contained in the microbubbles is contained in microbubbles with a diameter of 1.5 μm or less. The microbubbles can be obtained by preparing an emulsion comprising an aqueous medium, a phospholipid and a water immiscible organic solvent. The emulsion is then freeze-dried and then reconstituted in an aqueous suspension of gas-filled microbubbles. | 04-25-2013 |
20130295147 | GAS-FILLED MICROVESICLES FOR USE AS VACCINE - Gas-filled microvesicles comprising an antigen bound thereto and to aqueous suspensions containing said microvesicles, for use in immunomodulating formulations, in particular as a vaccine. The antigen is covalently bound to a component of the microvesicles envelope. The microvesicles of the invention are particularly effective in the uptake by antigen-presenting cells, in particular dendritic cells. | 11-07-2013 |
20140163366 | Automatic Liquid Injection System and Method - A power assisted method and injector device for controllably delivering to patients a dispersion medicament or diagnostically active agent, the homogeneity of which is preserved throughout delivery. Diagnostically active agents disclosed are gas microbubble suspensions useful in ultrasonic diagnostic imaging and liposomal formulations in which liposome vesicles are loaded with iodinated compounds. | 06-12-2014 |
Patent application number | Description | Published |
20090053252 | BIMER OR AN OLIGOMER OF A DIMER, TRIMER, QUATROMER OR PENTAMER OF RECOMBINANT FUSION PROTEINS - The invention relates to oligomers of a dimer, trimer, quatromer or pentamer of recombinant fusion proteins. Said oligomers are characterized in that the recombinant fusion proteins have at least one component A and at least one component B, whereby component A contains a protein or a protein segment with a biological function, in particular with a ligand function for antibodies, for soluble or membranous signal molecules, for receptors or an antibody, or an antibody segment, and component B contains a protein or a protein segment which dimerizes or oligomerizes the dimer, trimer, quatromer or pentamer of the recombinant fusion protein, without the action of third-party molecules. The invention also relates to the use of dimers or oligomers of this type for producing a medicament, to the fusion proteins which cluster in dimers or oligomers and to their DNA sequence and expression vectors or host cells comprising this DNA sequence. | 02-26-2009 |
20100233179 | BAFF, inhibitors thereof and their use in the modulation of B-cell response - The invention provides methods for treating or preventing disorders associated with expression of BAFF comprising BAFF and fragments thereof, antibodies, agonists and antagonists. | 09-16-2010 |
20100254984 | FUSION CONSTRUCTS CONTAINING ACTIVE SECTIONS OF TNF LIGANDS - Disclosed is a recombinant fusion protein containing an amino-acid sequence which comprises: (a) the Fc section or part of an Fc section of an immunoglobulin as component (A) or a functional variant of component (A); (b) the extracellular part of a TNF ligand or a partial sequence of the extracellular part of a TNF ligand as component (B) or a functional variant of component (B); and optionally (c) a transition area between component (A) and component (B), containing a linker. | 10-07-2010 |
20120009211 | BIMER OR AN OLIGOMER OF A DIMER, TRIMER, QUADROMER OR PENTAMER OF RECOMBINANT FUSION PROTEINS - The invention relates to oligomers of a dimer, trimer, quatromer or pentamer of recombinant fusion proteins. Said oligomers are characterized in that the recombinant fusion proteins have at least one component A and at least one component B, whereby component A contains a protein or a protein segment with a biological function, in particular with a ligand function for antibodies, for soluble or membranous signal molecules, for receptors or an antibody, or an antibody segment, and component B contains a protein or a protein segment which dimerizes or oligomerizes the dimer, trimer, quatromer or pentamer of the recombinant fusion protein, without the action of third-party molecules. The invention also relates to the use of dimers or oligomers of this type for producing a medicament, to the fusion proteins which cluster in dimers or oligomers and to their DNA sequence and expression vectors or host cells comprising this DNA sequence. | 01-12-2012 |
20120189634 | TACI AS AN ANTI-TUMOR AGENT - A method of treating a mammal for a condition associated with undesired cell proliferation comprising administering to said mammal an effective amount of a TACI reagent, wherein said reagent extends mean survival time of said mammal by about 10% or more as compared to the absence of administering the TACI reagent. | 07-26-2012 |
20120192296 | PREPARATION OF ISOLATED AGONIST ANTI-EDAR MONOCLONAL ANTIBODIES - The present invention concerns the preparation of substantially purified agonist anti-EDAR monoclonal antibodies or isolated monoclonal antibody fragments or antigen binding portions or fragments thereof. The invention further relates to isolated agonist anti-EDAR monoclonal antibodies or isolated monoclonal antibody fragments or antigen binding portions or fragments thereof as well as their use in the treatment of X-linked hypohidrotic ectodermal dysplasia and tooth agenesis. The invention also relates to a pharmaceutical composition comprising said isolated agonist anti-EDAR monoclonal antibodies or isolated monoclonal antibody fragments or antigen binding portions or fragments thereof and to a method of treating X-linked hypohidrotic ectodermal dysplasia and tooth agenesis. Finally, the present invention concerns a pharmaceutical kit comprising said isolated agonist anti-EDAR monoclonal antibodies or isolated monoclonal antibody fragments or antigen binding portions or fragments thereof. | 07-26-2012 |
20130202552 | BIMER OR AN OLIGOMER OF A DIMER, TRIMER, QUADROMER OR PENTAMER OF RECOMBINANT FUSION PROTEINS - The invention relates to oligomers of a dimer, trimer, quatromer or pentamer of recombinant fusion proteins. Said oligomers are characterized in that the recombinant fusion proteins have at least one component A and at least one component B, whereby component A contains a protein or a protein segment with a biological function, in particular with a ligand function for antibodies, for soluble or membrane signal molecules, for receptors or an antibody, or an antibody segment, and component B contains a protein or a protein segment which dimerizes or oligomerizes the dimer, trimer, quatromer or pentamer of the recombinant fusion protein, without the action of third-party molecules. The invention also relates to the use of dimers or oligomers of this type for producing a medicament, to the fusion proteins which cluster in dimers or oligomers and to their DNA sequence and expression vectors or host cells comprising this DNA sequence. | 08-08-2013 |
20130273046 | PREPARATION OF ISOLATED AGONIST ANTI-EDAR MONOCLONAL ANTIBODIES - The present invention concerns the preparation of substantially purified agonist anti-EDAR monoclonal antibodies or isolated monoclonal antibody fragments or antigen binding portions or fragments thereof. The invention further relates to isolated agonist anti-EDAR monoclonal antibodies or isolated monoclonal antibody fragments or antigen binding portions or fragments thereof as well as their use in the treatment of X-linked hypohidrotic ectodermal dysplasia and tooth agenesis. The invention also relates to a pharmaceutical composition comprising said isolated agonist anti-EDAR monoclonal antibodies or isolated monoclonal antibody fragments or antigen binding portions or fragments thereof and to a method of treating X-linked hypohidrotic ectodermal dysplasia and tooth agenesis. Finally, the present invention concerns a pharmaceutical kit comprising said isolated agonist anti-EDAR monoclonal antibodies or isolated monoclonal antibody fragments or antigen binding portions or fragments thereof. | 10-17-2013 |
20130295093 | FUSION CONSTRUCTS CONTAINING ACTIVE SECTIONS OF TNF LIGANDS - Disclosed is a recombinant fusion protein containing an amino-acid sequence which comprises: (a) the Fc section or part of an Fc section of an immunoglobulin as component (A) or a functional variant of component (A); (b) the extracellular part of a TNF ligand or a partial sequence of the extracellular part of a TNF ligand as component (B) or a functional variant of component (B); and optionally (c) a transition area between component (A) and component (B), containing a linker. | 11-07-2013 |
20150017161 | COMPOSITIONS AND METHODS FOR THE ALTERATION OF XLHED PHENOTYPES - The invention relates to methods for the temporal administration of EDA agonists, in particular EDI200, which correlate to optimal therapeutic response windows required for the formation of any EDA-dependent structures such as ectodermal appendages. Use of the methods described allow for the design of targeted therapeutic dosing and administration regimens in order to correct or alter abnormal phenotypes associated with genetic disorders, in particular, XLHED. | 01-15-2015 |
20150098944 | FUSION CONSTRUCTS CONTAINING ACTIVE SECTIONS OF TNF LIGANDS - Disclosed is a recombinant fusion protein containing an amino-acid sequence which comprises: (a) the Fc section or part of an Fc section of an immunoglobulin as component (A) or a functional variant of component (A); (b) the extracellular part of a TNF ligand or a partial sequence of the extracellular part of a TNF ligand as component (B) or a functional variant of component (B); and optionally (c) a transition area between component (A) and component (B), containing a linker. | 04-09-2015 |
20150139992 | BAFF RECEPTOR (BCMA), AN IMMUNOREGULATORY AGENT - A novel receptor in the TNF family is provided: BAFF-R. Chimeric molecules and antibodies to BAFF-R and methods of use thereof are also provided. | 05-21-2015 |
20150218247 | TACI AS AN ANTI-TUMOR AGENT - A method of treating a mammal for a condition associated with undesired cell proliferation comprising administering to said mammal an effective amount of a TACI reagent, wherein said reagent extends mean survival time of said mammal by about 10% or more as compared to the absence of administering the TACI reagent. | 08-06-2015 |
20160075789 | ANTI-ECTODYSPLASIN ANTIBODIES - The present invention relates to the preparation of substantially purified anti-EDA1 monoclonal antibodies or isolated monoclonal antibody fragments or antigen binding portions or fragments thereof as well as pharmaceutical compositions containing such antibodies. The antibodies may be used in the treatment of disorders relating to excessive action of EDA1 such as hirsutism, ectopic teeth, hyperhidrosis, breast cancer, dermal eccrine cylindroma or skin disorders such as sebaceous gland hyperplasia, comedones, milia, acne, seborrhea, rosacea, steatoma, and furuncles. The anti-EDA1 antibodies are also useful in immunoassays such as sandwich ELISA. | 03-17-2016 |
Patent application number | Description | Published |
20080319137 | ANTIOXIDANT STABILIZED CROSSLINKED ULTRA-HIGH MOLECULAR WEIGHT POLYETHYLENE FOR MEDICAL DEVICE APPLICATIONS - An antioxidant combined with UHMWPE prior to subjecting the UHMWPE to crosslinking irradiation. In one exemplary embodiment, the antioxidant is tocopherol. After the antioxidant is combined with the UHMWPE, the resulting blend may be formed into slabs, bar stock, and/or incorporated into a substrate, such as a metal, for example. The resulting product may then be subjected to crosslinking irradiation. In one exemplary embodiment, the UHMWPE blend is preheated prior to subjecting the same to crosslinking irradiation. Once irradiated, the UHMWPE blended product may be machined, packaged, and sterilized in accordance with conventional techniques. | 12-25-2008 |
20100029858 | ANTIOXIDANT STABILIZED CROSSLINKED ULTRA-HIGH MOLECULAR WEIGHT POLYETHYLENE FOR MEDICAL DEVICE APPLICATIONS - An antioxidant combined with UHMWPE prior to subjecting the UHMWPE to crosslinking irradiation. In one exemplary embodiment, the antioxidant is tocopherol. After the antioxidant is combined with the UHMWPE, the resulting blend may be formed into slabs, bar stock, and/or incorporated into a substrate, such as a metal, for example. The resulting product may then be subjected to crosslinking irradiation. In one exemplary embodiment, the UHMWPE blend is preheated prior to subjecting the same to crosslinking irradiation. Once irradiated, the UHMWPE blended product may be machined, packaged, and sterilized in accordance with conventional techniques. | 02-04-2010 |
20100137481 | POLYETHYLENE MATERIALS - Certain embodiments described herein are directed to polymer compositions including a base material, a secondary material and an antioxidant. The composition also includes crystalline regions and amorphous regions with the crystalline regions comprising at least 62% by volume of the composition. In some embodiments, the base material is an ultra high molecular weight polyethylene material and the secondary material is a polyethylene material that is different than the base material. | 06-03-2010 |
20110028600 | ANTIOXIDANT STABILIZED CROSSLINKED ULTRA-HIGH MOLECULAR WEIGHT POLYETHYLENE FOR MEDICAL DEVICE APPLICATIONS - An antioxidant combined with UHMWPE prior to subjecting the UHMWPE to crosslinking irradiation. In one exemplary embodiment, the antioxidant is tocopherol. After the antioxidant is combined with the UHMWPE, the resulting blend may be formed into slabs, bar stock, and/or incorporated into a substrate, such as a metal, for example. The resulting product may then be subjected to crosslinking irradiation. In one exemplary embodiment, the UHMWPE blend is preheated prior to subjecting the same to crosslinking irradiation. Once irradiated, the UHMWPE blended product may be machined, packaged, and sterilized in accordance with conventional techniques. | 02-03-2011 |
20110133371 | ANTIOXIDANT STABILIZED CROSSLINKED ULTRA-HIGH MOLECULAR WEIGHT POLYETHYLENE FOR MEDICAL DEVICE APPLICATIONS - An antioxidant combined with UHMWPE prior to subjecting the UHMWPE to crosslinking irradiation. In one exemplary embodiment, the antioxidant is tocopherol. After the antioxidant is combined with the UHMWPE, the resulting blend may be formed into slabs, bar stock, and/or incorporated into a substrate, such as a metal, for example. The resulting product may then be subjected to crosslinking irradiation. In one exemplary embodiment, the UHMWPE blend is preheated prior to subjecting the same to crosslinking irradiation. Once irradiated, the UHMWPE blended product may be machined, packaged, and sterilized in accordance with conventional techniques. | 06-09-2011 |
20120157591 | Antioxidant Stabilized Crosslinked Ultra-High Molecular Weight Polyethylene For Medical Device Applications - An antioxidant combined with UHMWPE prior to subjecting the UHMWPE to crosslinking irradiation. In one exemplary embodiment, the antioxidant is tocopherol. After the antioxidant is combined with the UHMWPE, the resulting blend may be formed into slabs, bar stock, and/or incorporated into a substrate, such as a metal, for example. The resulting product may then be subjected to crosslinking irradiation. In one exemplary embodiment, the UHMWPE blend is preheated prior to subjecting the same to crosslinking irradiation. Once irradiated, the UHMWPE blended product may be machined, packaged, and sterilized in accordance with conventional techniques. | 06-21-2012 |
20140194934 | ANTIOXIDANT STABALIZED CROSSLINKED ULTRA HIGH MOLECULAR WEIGHT POLYETHYLENE FOR MEDICAL DEVICE APPLICATIONS - An antioxidant combined with UHMWPE prior to subjecting the UHMWPE to crosslinking irradiation. In one exemplary embodiment, the antioxidant is tocopherol. After the antioxidant is combined with the UHMWPE, the resulting blend may be formed into slabs, bar stock, and/or incorporated into a substrate, such as a metal, for example. The resulting product may then be subjected to crosslinking irradiation. In one exemplary embodiment, the UHMWPE blend is preheated prior to subjecting the same to crosslinking irradiation. Once irradiated, the UHMWPE blended product may be machined, packaged, and sterilized in accordance with conventional techniques. | 07-10-2014 |
20140194935 | ANTIOXIDANT STABILIZED CROSSLINKED ULTRA-HIGH MOLECULAR WEIGHT POLYETHYLENE FOR MEDICAL DEVICE APPLICATIONS - An antioxidant combined with UHMWPE prior to subjecting the UHMWPE to crosslinking irradiation. In one exemplary embodiment, the antioxidant is tocopherol. After the antioxidant is combined with the UHMWPE, the resulting blend may be formed into slabs, bar stock, and/or incorporated into a substrate, such as a metal, for example. The resulting product may then be subjected to crosslinking irradiation. In one exemplary embodiment, the UHMWPE blend is preheated prior to subjecting the same to crosslinking irradiation. Once irradiated, the UHMWPE blended product may be machined, packaged, and sterilized in accordance with conventional techniques. | 07-10-2014 |
20160108184 | ANTIOXIDANT STABILIZED CROSSLINKED ULTRA HIGH MOLECULAR WEIGHT POLYETHYLENE FOR MEDICAL DEVICE APPLICATIONS - An antioxidant combined with UHMWPE prior to subjecting the UHMWPE to crosslinking irradiation. In one exemplary embodiment, the antioxidant is tocopherol. After the antioxidant is combined with the UHMWPE, the resulting blend may be formed into slabs, bar stock, and/or incorporated into a substrate, such as a metal, for example. The resulting product may then be subjected to crosslinking irradiation, In one exemplary embodiment, the UHMWPE blend is preheated prior to subjecting the same to crosslinking irradiation. Once irradiated, the UHMWPE blended product may be machined, packaged, and sterilized in accordance with conventional techniques. | 04-21-2016 |
Patent application number | Description | Published |
20100111598 | CONNECTING MEANS AND METHOD OF PRODUCING A CONNECTION BETWEEN A FIRST COMPONENT AND A SECOND COMPONENT - In order to produce a connecting means for connecting a first component and a second component particularly for connecting furniture parts or machine parts which will enable two components to be connected to one another by means of a reliably releasable connection without giving rise to the danger of damaging the two components during the assembly process wherein the device comprises a first connecting element that it arranged on the first component in the connected state of the components and a second connecting element that is arranged on the second component in the connected state of the components and wherein at least one of the connecting elements comprises a curved bearing surface which is in the form of an arc of a circle in longitudinal section, it is proposed that the first connecting element and the second connecting element be connected to one another in releasable manner in the connected state of the components and that at least the first connecting element should comprise a housing and at least one holding element which is moveable relative to the housing of the first connecting element and which, in a holding position, cooperates with the second connecting element in such a way that a relative movement of the first connecting element and the second connecting element along a direction of connection is prevented, and which, in a release position, permits a relative movement of the first connecting element and the second connecting element along the direction of the connection wherein at least one holding element is movable from the holding position into the release position and/or from the release position into the holding position by an action taken outside the connecting means and wherein the housing ( | 05-06-2010 |
20100111599 | CONNECTING MEANS AND METHOD OF PRODUCING A CONNECTION BETWEEN A FIRST COMPONENT AND A SECOND COMPONENT - In order to produce a connecting means for connecting a first component and a second component and especially for connecting furniture parts or machine parts which will enable two components consisting of a multiplicity of materials to be securely connected to one another without giving rise to the danger of damaging the two components during the assembly process, wherein the device comprises a first connecting element that it arranged on the first component in the connected state of the components and a second connecting element that is arranged on the second component in the connected state of the components, it is proposed that at least one of the connecting elements should comprise a non self-cutting holding projection which has a curved support surface that is in the form of an arc of a circle in longitudinal section, wherein the holding projection can be inserted into a groove which is provided in one of the components and has a curved undercut surface that is in the form of an arc of a circle in longitudinal section. | 05-06-2010 |
20120328386 | CONNECTING MEANS AND METHOD OF PRODUCING A CONNECTION BETWEEN A FIRST COMPONENT AND A SECOND COMPONENT - A connecting means for connecting a first component and a second component, which enables two components to be securely connected to one another without giving rise to the danger of damaging the two components during the assembly process, comprises a first connecting element that is arranged on the first component in the connected state of the components and a second connecting element that is arranged on the second component in the connected state of the components, wherein at least one of the connecting elements comprises a non self-cutting holding projection which has a curved support surface that is in the form of an arc of a circle in longitudinal section, wherein the holding projection is inserted into a groove which is provided in one of the components and has a curved undercut surface that is in the form of an arc of a circle in longitudinal section. | 12-27-2012 |
20140321934 | CONNECTING MEANS AND METHOD OF PRODUCING A CONNECTION BETWEEN A FIRST COMPONENT AND A SECOND COMPONENT - In order to produce a connecting means for connecting a first component and a second component and especially for connecting furniture parts or machine parts which will enable two components consisting of a multiplicity of materials to be securely connected to one another without giving rise to the danger of damaging the two components during the assembly process, wherein the device comprises a first connecting element that it arranged on the first component in the connected state of the components and a second connecting element that is arranged on the second component in the connected state of the components, it is proposed that at least one of the connecting elements should comprise a non self-cutting holding projection which has a curved support surface that is in the form of an arc of a circle in longitudinal section, wherein the holding projection can be inserted into a groove which is provided in one of the components and has a curved undercut surface that is in the form of an arc of a circle in longitudinal section. | 10-30-2014 |